Emergent BioSolutions Reports Financial Results For Second Quarter 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Emergent BioSolutions (EBS) Misses Q2 EPS by $1.21
July 29, 2021 4:17 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.33, $1.21 worse than the analyst estimate of $1.54. Revenue for the quarter came in at $397.5 million versus the consensus estimate of $398.93 million.
GUIDANCE:
Emergent BioSolutions sees Q3 2021 revenue of $1700-1900 billion, versus the consensus of... More
